Risk factors associated with adverse events leading to withdrawal of biologic agents.
| Variables | OR | 95% CI | p | Multiple Regression p, stepwise method |
|---|---|---|---|---|
| Age, yrs | ||||
| < 65 yrs vs ≥ 65 yrs | 2.68 | 1.31–5.48 | < 0.01 | 0.015 |
| Disease duration, weeks | — | — | 0.08 | 0.617 |
| Sex | 1.55 | 0.66–3.64 | 0.34 | |
| DAS28-ESR | — | — | 0.86 | |
| HAQ-DI | — | — | 0.12 | 0.090 |
| Current smoking | 1.31 | 0.61–2.80 | 0.54 | |
| Brinkman index | — | 0.39 | ||
| Concomitant use of MTX | 0.49 | 0.22–1.13 | 0.14 | 0.151 |
| mg/weeks | — | — | 0.22 | |
| Amount, mg | — | — | 0.22 | |
| Concomitant use of PSL | 1.48 | 0.73–2.97 | 0.27 | |
| mg/day | — | — | 0.91 | |
| Amount, mg | — | — | 0.71 | |
| Biologics | ||||
| TNFi | — | — | ||
| TCZ | — | — | 0.26 | |
| ABA | — | — | ||
| Pulmonary diseases | 2.76 | 1.31–5.81 | 0.01 | < 0.01 |
| Cardiovascular diseases | 2.26 | 0.78–6.54 | 0.17 | 0.086 |
| Lifestyle diseases | 1.32 | 0.62–2.80 | 0.54 | |
| Renal function | ||||
| eGFR | — | 0.103 | 0.151 |
Significant data are in bold face. DAS28: 28-joint Disease Activity Score; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire–Disability Index; MTX: methotrexate; PSL: prednisolone; TNFi: tumor necrosis factor inhibitor; TCZ: tocilizumab; ABA: abatacept; eGFR: estimated glomerular filtration rate.